MEMPHIS, Tenn., Aug. 26, 2021 /PRNewswire/ -- Research from
a large international effort shows that 20% of children with cancer
who are infected with SARS-CoV-2 develop severe infections. In
studies of children overall, only 1-6% have reported severe
infections. The results come from the Global Registry of COVID-19
in Childhood Cancer, which was launched by St. Jude Children's
Research Hospital and the International Society of Paediatric
Oncology (SIOP). The registry gathers data on the pandemic's effect
on this unique patient population. The findings were published
today in The Lancet Oncology.
Scientists from St. Jude and SIOP
report results from the Global Registry of COVID-19 and Childhood
Cancer.
Results from the registry indicated that in addition to more
severe or critical infections, pediatric cancer patients were more
likely to be hospitalized and die than were other children. The
pandemic also disrupted cancer treatment. These effects were
observed more significantly in low- and middle-income countries,
where the odds of severe or critical disease from COVID-19 were
nearly 6 times higher than in high-income countries.
"The results clearly and definitively show that children with
cancer fare worse with COVID-19 than children without cancer," said
corresponding author Sheena Mukkada,
M.D., St. Jude Departments of Global Pediatric Medicine and
Infectious Diseases. "This global collaboration helps clinicians
make evidence-based decisions about prevention and treatment,
which, unfortunately, remain relevant as the pandemic
continues."
A greater burden for childhood cancer patients
This is the first multinational study to describe the outcomes
of a large cohort of children and adolescents with cancer or
hematopoietic stem cell transplantation and laboratory diagnosis of
COVID-19. The registry remains open and is enrolling children
younger than 19 years old.
The analysis looked at 1,500 children from 131 hospitals in 45
countries from April 15, 2020, to
February 1, 2021. This is prior to
vaccinations becoming available to older children in some areas of
the globe, as well as prior to the emergence of certain disease
variants, including delta, which are responsible for the new surge
and have become a major global concern.
The study found that 65% of patients were hospitalized and 17%
required admission or transfer to a higher level of care. It also
showed that 4% of patients died due to COVID-19 infections,
compared to 0.01-0.7% mortality reported among general pediatric
patients. Cancer care was also affected. Cancer therapy was
modified in 56% of patients and 45% had chemotherapy withheld while
their infections were treated.
"By working together to create this global registry, we have
enabled hospitals around the world to rapidly share and learn how
COVID-19 is affecting children with cancer," said the paper's
co-author, Professor Kathy
Pritchard-Jones, SIOP president. "The results are reassuring
that many children can continue their cancer treatment safely, but
they also highlight important clinical features that may predict a
more severe clinical course and the need for greater vigilance for
some patients."
A global pandemic and a global response
The registry suggests biologic factors that likely influence how
children with cancer respond to COVID-19. Those include immune
system function and the underlying disease. Analysis also showed
that outcomes vary around the world, although the registry does not
pinpoint causes. This variation may be due to a multitude of
factors, including disruptions from the pandemic, access to care
and resources, or delays in infection diagnosis.
Results from the registry are a call to action to address
inequities in access to protective and effective treatment measures
against the COVID-19 pandemic worldwide.
"Understanding a global crisis like COVID-19 requires our entire
childhood cancer community around the world to come together to
respond," said senior author Carlos
Rodriguez-Galindo, M.D., St. Jude Global director. "The
impact of this disease has been felt in every corner of the world,
but particularly in low- and middle-income countries compared to
high-income countries. There are critical differences based on
where a child lives. This registry is a tool that is helping
us understand what that means for children with cancer
everywhere."
The registry is still enrolling patients and continues to add
new countries. It includes freely available data-visualization
tools so that anyone, anywhere, can access the information.
Learn more about COVID-19 and vaccination
Vaccinations against COVID-19 have been demonstrated to be safe
and effective in preventing severe forms of the disease, helping
patients avoid hospitalizations and the need for mechanical
ventilation. In the United States,
vaccines are available and encouraged for children 12 years of age
and older. Vaccination is one way to protect not only yourself but
your community, including those who are at high risk of severe
disease such as children with cancer.
Learn more about how Vaccines Bring Us Closer and check out
COVID-19 resources from St.
Jude.
Authors and Funding
The study's other authors are Guillermo Chantada, Hospital San
Joan de Deu Barcelona, Spain;
Rashmi Dalvi, Bombay Hospital
Institute of Medical Sciences Mumbai,
India; Laila Hessissen, Mohammed V University Rabat, Morocco; Michael Sullivan, University of Melbourne, Australia; Eric Bouffet,
Hospital for Sick Children Toronto,
Canada; Nickhill Bhakta, Yichen
Chen, Yuvanesh Vedaraju, Lane
Faughnan, Maysam Homsi,
Hilmarie Muniz-Talavera, Radhikesh Ranadive, Monika Metzger, Paola
Friedrich, Asya Agulnik,
Sima Jeha, Catherina Lam, Daniel
Moreira, Victor Santana,
Miguela Caniza and Meenakshi Devidas of St. Jude; and more than 150 members of the
Global Registry of COVID-19 in Childhood Cancer.
The study was funded by the National Institutes of Health
(Cancer Center Support grant CA21765), and ALSAC, the fundraising
and awareness organization of St.
Jude.
About SIOP
Established in 1969, the International Society of Paediatric
Oncology (SIOP), is the only global multidisciplinary society
entirely devoted to paediatric and adolescent cancer. The society
has over 1,800 members worldwide including physicians, nurses,
other health-care professionals, scientists and researchers. Our
members are dedicated to increasing knowledge about all aspects of
childhood cancer. SIOP envisions that "no child should die of
cancer" and is aiming to improve the lives of children and
adolescents with cancer through global collaboration, education,
training, research and advocacy. To learn more, visit
siop-online.org or follow SIOP on social media at @WorldSIOP.
About St. Jude Global
St. Jude Children's Research Hospital established the Department
of Global Pediatric Medicine in 2016 as a new academic department
to address the global challenges in pediatric cancer and
catastrophic diseases, and to build on its previous work to reduce
disparities in access to care. As a result, St. Jude Global
launched in 2018 to support the advancement of care for children
with cancer and other catastrophic diseases through the development
of comprehensive initiatives in capacity building, education and
research. St. Jude Global is committed to ensuring that every child
will have access to quality care and treatment no matter where in
the world they live.
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital is leading the way the
world understands, treats and cures childhood cancer and other
life-threatening diseases. It is the only National Cancer
Institute-designated Comprehensive Cancer Center devoted solely to
children. Treatments developed at St.
Jude have helped push the overall childhood cancer survival
rate from 20% to 80% since the hospital opened more than 50 years
ago. St. Jude freely shares the
breakthroughs it makes, and every child saved at St. Jude means doctors and scientists
worldwide can use that knowledge to save thousands more children.
Families never receive a bill from St.
Jude for treatment, travel, housing and food — because all a
family should worry about is helping their child live. To learn
more, visit stjude.org or follow St.
Jude on social media at @stjuderesearch.
![Carlos Rodriguez-Galindo, M.D., St. Jude Global director, issues a call to action to address inequities in access to protective and effective treatment measures against the COVID-19 pandemic worldwide. Carlos Rodriguez-Galindo, M.D., St. Jude Global director, issues a call to action to address inequities in access to protective and effective treatment measures against the COVID-19 pandemic worldwide.](https://mma.prnewswire.com/media/1600151/St_Jude_Carlos_Rodriguez_Galindo.jpg)
View original content to download
multimedia:https://www.prnewswire.com/news-releases/covid-19-in-children-with-cancer-severe-disease-and-disrupted-treatment-301361700.html
SOURCE St. Jude Children's Research Hospital